n.a. (ARIA)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
ARIAD To Present At The 35th Annual J.P. Morgan Healthcare Conference

ARIAD To Present At The 35th Annual J.P. Morgan Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), a rare cancer-focused innovative biotechnology company, today announced that it will present at the 35th Annual J.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

A look back at the year's worth of Adam Feuerstein's biotech tweets.

Dow Scores Another Record for Third Consecutive Day; S&P 500 Also Hits New High

Dow Scores Another Record for Third Consecutive Day; S&P 500 Also Hits New High

The Dow Jones Industrial Average's winning streak continued after closing higher for the 18th time in 22 sessions. The S&P 500 also hit a new record high.

Dow, S&P 500 Trade at Session Highs in Broad Wall Street Rally

Dow, S&P 500 Trade at Session Highs in Broad Wall Street Rally

The S&P 500 and Dow Jones Industrial Average trade at session highs early Wednesday afternoon as a broad rally overshadows a slump in health care stocks.

S&P 500 and Dow Reverse Losses to Post Intraday Records

S&P 500 and Dow Reverse Losses to Post Intraday Records

The S&P 500 reverses an earlier loss to post small gains, trading at a new intraday record, thanks to broad gains across all sectors save for health care.

ARIAD's Investigational Medicine Brigatinib Demonstrated 15.6 Month Systemic Median Progression-Free Survival In ALTA Study

ARIAD's Investigational Medicine Brigatinib Demonstrated 15.6 Month Systemic Median Progression-Free Survival In ALTA Study

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), a rare cancer-focused innovative biotechnology company, today announced clinical data on brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, from...

ARIAD Announces Data Presentations At American Society Of Hematology Meeting

ARIAD Announces Data Presentations At American Society Of Hematology Meeting

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the results of clinical and translational studies on Iclusig ® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with...

ARIAD Presents Updated Brigatinib Data With 18.4 Months Median Intracranial Progression Free Survival (PFS) In ALK+ NSCLC Patients With CNS Metastases At The World Conference On Lung Cancer

ARIAD Presents Updated Brigatinib Data With 18.4 Months Median Intracranial Progression Free Survival (PFS) In ALK+ NSCLC Patients With CNS Metastases At The World Conference On Lung Cancer

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), a rare cancer-focused innovative biotechnology company, today announced clinical data on brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, from...

ARIAD To Host Webcast And Conference Call On Brigatinib Data Presentations At The World Conference On Lung Cancer

ARIAD To Host Webcast And Conference Call On Brigatinib Data Presentations At The World Conference On Lung Cancer

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA), a rare cancer-focused innovative biotechnology company, today announced a conference call and webcast to discuss the clinical data presented on brigatinib, the Company's...

ARIAD Announces Data Presentations At The World Conference On Lung Cancer

ARIAD Announces Data Presentations At The World Conference On Lung Cancer

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), a rare cancer-focused innovative biotechnology company, today announced that clinical data on brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor,...

The Inaugural ALK+ Day Is November 15, During Lung Cancer Awareness Month. (Photo: Business Wire)

The Inaugural ALK+ Day Is November 15, During Lung Cancer Awareness Month. (Photo: Business Wire)

In recognition of this month's Lung Cancer Awareness Month, ARIAD Pharmaceuticals, Inc.

'Mad Money' Lightning Round: 'Health Care Is All Over the Map'

'Mad Money' Lightning Round: 'Health Care Is All Over the Map'

Jim Cramer urges caution with phamaceutical companies Supernus and Ariad

Jim Cramer's 'Mad Money' Recap: Markets Pivot From Shocked to Bullish

Jim Cramer's 'Mad Money' Recap: Markets Pivot From Shocked to Bullish

Jim Cramer explains the rotation, looks ahead to next week.

ARIAD Announces Phase 1/2 Trial Data On Investigational Drug Brigatinib Published In The Lancet Oncology

ARIAD Announces Phase 1/2 Trial Data On Investigational Drug Brigatinib Published In The Lancet Oncology

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced clinical data on its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, were published in The Lancet Oncology (Gettinger, S.

ARIAD Reports Third Quarter 2016 Financial Results

ARIAD Reports Third Quarter 2016 Financial Results

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the third quarter and first nine months of 2016.

Why Incyte's Shares Could Soon Hit $100

Why Incyte's Shares Could Soon Hit $100

The drug company reported strong earnings.

ARIAD To Present At The Jefferies 2016 London Healthcare Conference

ARIAD To Present At The Jefferies 2016 London Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Jefferies 2016 London Healthcare Conference.

ARIAD To Webcast Conference Call On Third Quarter 2016 Financial Results

ARIAD To Webcast Conference Call On Third Quarter 2016 Financial Results

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its third quarter 2016 financial results on Monday, November 7, 2016, before the market opens.

ARIAD Announces U.S. Food And Drug Administration Acceptance Of NDA Filing For Brigatinib

ARIAD Announces U.S. Food And Drug Administration Acceptance Of NDA Filing For Brigatinib

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the U.

SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Ariad Pharmaceuticals Inc. And Advises Investors With Losses To Contact The Firm

SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Ariad Pharmaceuticals Inc. And Advises Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Ariad Pharmaceuticals Inc.

Pardon Me, but I Have a Few Things to Say... Vertex, Biogen, Ariad, Sarepta

Pardon Me, but I Have a Few Things to Say... Vertex, Biogen, Ariad, Sarepta

More about Vertex's Debbie Downer gene, Biogen's Alzheimer's spin and Sarepta caught in drug launch purgatory.

ARIAD Announces Publication Of The Preclinical Profile Of Brigatinib In The Journal Clinical Cancer Research

ARIAD Announces Publication Of The Preclinical Profile Of Brigatinib In The Journal Clinical Cancer Research

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the publication of preclinical data on brigatinib, its investigational oral tyrosine kinase inhibitor in development for the treatment of patients with...

Ariad Pharmaceuticals (ARIA) Stock Downgraded at JMP Securities

Ariad Pharmaceuticals (ARIA) Stock Downgraded at JMP Securities

Ariad Pharmaceuticals' (ARIA) stock rating was decreased to 'market perform' at JMP Securities on Tuesday.

Analysts' Actions -- Chesapeake, McCormick, Time Warner, VF Corp. and More

Analysts' Actions -- Chesapeake, McCormick, Time Warner, VF Corp. and More

Here are Tuesday's top research calls, including upgrades for Chesapeake Energy, McCormick and Time Warner, and a downgrade for VF Corp.

Ariad Pharmaceuticals (ARIA) Stock Drops, JPMorgan Downgrades

Ariad Pharmaceuticals (ARIA) Stock Drops, JPMorgan Downgrades

Ariad Pharmaceuticals' (ARIA) stock rating was cut to 'underweight' at JPMorgan on Monday.

Analysts' Actions -- Kinder Morgan, AT&T, Verizon, 3M and More

Analysts' Actions -- Kinder Morgan, AT&T, Verizon, 3M and More

Here are Monday's top research calls, including upgrades for Kinder Morgan, Verizon and 3M, and a downgrade for AT&T.

'Mad Money' Lightning Round: United and Southwest Better Than JetBlue?

'Mad Money' Lightning Round: United and Southwest Better Than JetBlue?

Jim Cramer says he likes LUV and UAL, but JBLU is not a favorite.